Stock Performance and Market Context
On the trading day, Syngene International Ltd’s shares touched an intraday low of Rs.441.2, representing a 4.14% decline from the previous close. The stock has been on a downward trajectory for three consecutive sessions, cumulatively losing 7.49% over this period. This underperformance is notable against the Healthcare Services sector, where Syngene lagged by 2.65% on the day.
Further technical indicators highlight the bearish trend, with the stock currently trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day. This broad weakness contrasts with the broader market, where the Sensex opened flat but traded down by 0.23% to 83,125.70 points, remaining within 3.65% of its 52-week high of 86,159.02. The Sensex itself is positioned below its 50-day moving average, though the 50DMA remains above the 200DMA, signalling mixed market conditions.
Over the past year, Syngene International Ltd’s stock has delivered a negative return of 40.47%, significantly underperforming the Sensex’s positive 6.49% gain over the same period. The stock’s 52-week high was Rs.760.95, underscoring the extent of the recent decline.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Financial Performance and Valuation Concerns
Syngene International Ltd’s recent quarterly results have contributed to the subdued market sentiment. For the quarter ended December 2025, the company reported a Profit Before Tax (PBT) excluding other income of Rs.83.60 crores, reflecting a decline of 37.8% compared to the average of the previous four quarters. Net Profit After Tax (PAT) for the same period was Rs.52.29 crores, down 55.3% from the prior four-quarter average. Earnings Per Share (EPS) also hit a low of Rs.0.37, marking the weakest quarterly EPS in recent periods.
Long-term growth metrics further illustrate the challenges faced by the company. Over the last five years, net sales have grown at an annualised rate of 11.77%, while operating profit has expanded at a more modest 5.36% per annum. These growth rates have not translated into strong returns for shareholders, as evidenced by the stock’s negative 40.47% return over the past year and an 18.5% decline in profits during the same timeframe.
From a valuation standpoint, Syngene International Ltd is trading at a premium relative to its peers. The company’s Return on Equity (ROE) stands at 9.9%, while its Price to Book Value ratio is 3.9, indicating a relatively expensive valuation given the subdued profitability and growth profile. This premium valuation has been a factor in the stock’s underperformance, as investors weigh the company’s fundamentals against its market price.
Comparative Performance and Market Position
Syngene International Ltd’s performance has been below par not only in the recent year but also over longer periods. The stock has underperformed the BSE500 index over the last three years, one year, and three months, signalling persistent challenges in delivering shareholder value. Despite operating in the Healthcare Services sector, which generally benefits from steady demand, the company’s returns have lagged sectoral and market benchmarks.
On a positive note, the company maintains a conservative capital structure with an average Debt to Equity ratio of zero, indicating no reliance on debt financing. Institutional investors hold a significant 40.8% stake in the company, reflecting confidence from entities with substantial analytical resources. However, this has not translated into upward price momentum in recent months.
Why settle for Syngene International Ltd? SwitchER evaluates this Healthcare Services small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Mojo Score and Analyst Ratings
Reflecting the company’s recent performance and outlook, Syngene International Ltd holds a Mojo Score of 28.0, categorised as a Strong Sell. This rating was upgraded from a Sell grade on 19 Jan 2026, signalling increased caution among analysts. The company’s Market Cap Grade is 3, indicating a mid-tier market capitalisation relative to other listed entities.
The Strong Sell rating is driven by the combination of weak profit growth, declining quarterly earnings, and a valuation premium that is not supported by operational metrics. These factors have contributed to the stock’s decline to its current 52-week low.
Summary of Key Metrics
To summarise, Syngene International Ltd’s stock has reached a new 52-week low of Rs.441.2, down 3.55% on the day and underperforming its sector by 2.65%. The stock’s one-year return stands at -40.47%, with profits falling by 18.5% over the same period. Quarterly results for December 2025 showed a 37.8% drop in PBT and a 55.3% decline in PAT compared to the previous four-quarter average. The company’s valuation remains elevated with a Price to Book Value of 3.9 and an ROE of 9.9%. Institutional holdings remain high at 40.8%, while the company maintains a zero debt position.
These factors collectively explain the stock’s recent price weakness and its position at a 52-week low, reflecting the market’s assessment of the company’s current financial and valuation profile.
Unlock special upgrade rates for a limited period. Start Saving Now →
